Conduit Pharmaceuticals
About: Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.
Employees: 6
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0.43% more ownership
Funds ownership: 7.29% [Q4 2024] → 7.72% (+0.43%) [Q1 2025]
24% less funds holding
Funds holding: 45 [Q4 2024] → 34 (-11) [Q1 2025]
35% less capital invested
Capital invested by funds: $599K [Q4 2024] → $387K (-$212K) [Q1 2025]
69% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 16
84% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 25
Research analyst outlook
We haven’t received any recent analyst ratings for CDT.
Financial journalist opinion
Based on 4 articles about CDT published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
Conduit Pharmaceuticals Enters Joint Development Agreement with Manoira to Advance AZD1656 and AZD5658 in Animal Health
Collaboration leverages cutting-edge reformulation expertise to generate cross-species insights, fast-track human clinical programs, and seeks to capture commercial potential in the $15 billion animal health market Evaluation of AZD5658 expands Conduit's glucokinase activator platform into novel veterinary applications, complementing AZD1656 development Cost-efficient approach enhances Conduit's pipeline while preserving full ownership of intellectual property and data, maximizing shareholder value Synergistic combination therapies under evaluation could redefine treatment standards in veterinary and human applications NAPLES, Fla. and CAMBRIDGE, United Kingdom, June 04, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”) today announced that it has entered into a joint development agreement with Manoira Corporation (“Manoira”), a privately held specialty animal health company specializing in proprietary reformulation technologies to create novel therapeutics for veterinary and livestock applications.
Neutral
GlobeNewsWire
3 weeks ago
Conduit Pharmaceuticals Inc. Listing on Nasdaq Capital Market
NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 22, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development, announces that, following confirmation of compliance with the Bid Price and Equity Requirements as detailed in the announcement dated May 21, 2025, the Company received formal notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company's application to transfer the listing of its common stock to The Nasdaq Capital Market has been approved and the Company's securities will be transferred to The Nasdaq Capital Market at the opening of business on May 23, 2025.
Neutral
GlobeNewsWire
3 weeks ago
Conduit Pharmaceuticals Inc. Regains Nasdaq Compliance
Conduit regains compliance with Bid Price and Equity Requirements CDT will continue to be listed and traded on The Nasdaq Stock Market NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 21, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development, announced that the Company received formal notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq's minimum bid price requirement (the “Bid Price Requirement”) set forth in Nasdaq Listing Rule 5550(a)(2), as well as Nasdaq's stockholders' equity requirement (“Equity Requirement”) set forth in Nasdaq Listing Rule 5550(b)(1).
Neutral
GlobeNewsWire
4 weeks ago
Conduit Pharmaceuticals Inc. Announces Reverse Stock Split
NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 16, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development, announces that its board of directors has approved a 1-for-15 reverse stock split of the Company's common stock.
Neutral
GlobeNewsWire
1 month ago
Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
Conduit secures a composition of matter patent from the Korean Intellectual Property Office for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune disorders, positioning the Company for clinical development and strategic partnerships. NAPLES, Fla.
Neutral
GlobeNewsWire
1 month ago
Conduit Pharmaceuticals Files Composition of Matter Patent for AZD5904 Creating Robust IP Foundation for Pipeline Asset
New patent filing secures composition of matter protection for AZD5904, a potent myeloperoxidase inhibitor in Conduit's pipeline, unlocking up to 20 years of new IP runway and enabling enhanced formulation strategies to target a broad range of diseases. NAPLES, Fla.
Neutral
GlobeNewsWire
1 month ago
Conduit Pharmaceuticals Announces Leadership Changes
NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 16, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the "Company") today announced key leadership changes to support the company's next phase of growth and execution.
Neutral
GlobeNewsWire
2 months ago
Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects
Conduit Pharmaceuticals files next generation cocrystal patent for VTAMA ® (tapinarof) which the Company believes could be a superior asset with both inflammatory and autoimmune prospectives just as the drug approaches 2027 exclusivity expiration, positioning the Company for high-value licensing partnerships. NAPLES, Fla.
Neutral
GlobeNewsWire
2 months ago
Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
Conduit secures a composition of matter patent from the USPTO for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune disorders, positioning the Company for clinical development and strategic partnerships. NAPLES, Fla.
Neutral
GlobeNewsWire
2 months ago
Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904
Conduit Pharmaceuticals advances its pipeline with key progress in preclinical lupus studies for AZD5658, Phase IIa trial design for AZD1656, formulation optimization, and IP expansion, positioning the Company for near-term milestones and growth. NAPLES, Fla.
Charts implemented using Lightweight Charts™